Global Contraceptive Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Contraceptive Market size is expected to reach USD 53.22 Billion in 2034 from USD 29.71 Billion (2025) growing at a CAGR of 6.69% during 2026-2034.

The global contraceptive market has grown steadily due to increasing awareness of family planning, reproductive health initiatives, and government-supported population control programs. Products such as oral contraceptives, condoms, intrauterine devices (IUDs), injectables, and implants are widely used across developed and emerging markets. Expansion of sexual health education and improved access to healthcare services have further driven adoption.

Major growth drivers include rising female workforce participation, delayed parenthood trends, and supportive public health policies. Technological advancements in long-acting reversible contraceptives (LARCs) and improved safety profiles have increased consumer confidence. E-commerce platforms and telehealth consultations have also enhanced product accessibility and privacy.

Future prospects are strong, with continued innovation in non-hormonal and male contraceptive options under development. Expansion of reproductive rights awareness and healthcare funding in emerging regions will likely support further growth. However, regulatory, cultural, and ethical considerations may influence market dynamics in certain countries. Overall, sustained demand for effective and convenient birth control methods underpins positive long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

Devices
Condoms (Male, Female)
Intra-Uterine Devices (Hormonal Iud, Copper Iud)
Vaginal Rings
Subdermal Implants
Diaphragms
Contraceptive Sponges
Drugs
Oral Contraceptive Pills
Injectable Contraceptives
Topical Contraceptives

By Age Group

15 - 44 Years
Above 44 Years

By Distribution Channels

Retail Pharmacies
Hospital Pharmacies
Online Channels
Other Distribution Channels

COMPANIES PROFILED

Afaxys Inc, Agile Therapeutics, Amneal Pharmaceuticals, Bayer AG, Church Dwight Co Inc, Cooper Companies, Evofem Biosciences, HRA Pharma, Maxwellia Ltd, Mayer Laboratories Inc, Mithra Pharmaceuticals, Organon Co

We can customise the report as per your requriements

Product Code: VMR11210455

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL CONTRACEPTIVE MARKET: BY PRODUCT 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Product
4.2. Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Condoms (Male, Female) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Intra-Uterine Devices (Hormonal Iud, Copper Iud) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Vaginal Rings Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Subdermal Implants Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.7. Diaphragms Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.8. Contraceptive Sponges Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.9. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.10. Oral Contraceptive Pills Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.11. Injectable Contraceptives Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.12. Topical Contraceptives Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CONTRACEPTIVE MARKET: BY AGE GROUP 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Age Group
5.2. 15 - 44 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Above 44 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CONTRACEPTIVE MARKET: BY DISTRIBUTION CHANNELS 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Distribution Channels
6.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Online Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.5. Other Distribution Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CONTRACEPTIVE MARKET: BY REGION 2022-2034(USD MN)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Product
- 7.2.2 By Age Group
- 7.2.3 By Distribution Channels
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Product
- 7.3.2 By Age Group
- 7.3.3 By Distribution Channels
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Product
- 7.4.2 By Age Group
- 7.4.3 By Distribution Channels
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Product
- 7.5.2 By Age Group
- 7.5.3 By Distribution Channels
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Product
- 7.6.2 By Age Group
- 7.6.3 By Distribution Channels
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CONTRACEPTIVE INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 Afaxys Inc
- 9.2.2 Agile Therapeutics
- 9.2.3 Amneal Pharmaceuticals
- 9.2.4 Bayer AG
- 9.2.5 Church & Dwight Co. Inc
- 9.2.6 Cooper Companies
- 9.2.7 Evofem Biosciences
- 9.2.8 HRA Pharma
- 9.2.9 Maxwellia Ltd
- 9.2.10 Mayer Laboratories Inc
- 9.2.11 Mithra Pharmaceuticals
- 9.2.12 Organon & Co